Soluble TGFBI aggravates the malignancy of cholangiocarcinoma through activation of the ITGB1 dependent PPARγ signalling pathway.
Jungwhoi LeeJungsul LeeWoogwang SimJae-Hoon KimPublished in: Cellular oncology (Dordrecht) (2022)
Our data suggest that TGFBI may serve as a promising prognostic biomarker and therapeutic target for cholangiocarcinoma.